APA (7th ed.) Citation

ML, A., MJ, T., JF, D., M, H., EM, S., AC, S., . . . JS, B. (2025). Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study. Blood, 146(9), 1065. https://doi.org/10.1182/blood.2025028357

Chicago Style (17th ed.) Citation

ML, Arellano, et al. "Menin Inhibition with Revumenib for NPM1-mutated Relapsed or Refractory Acute Myeloid Leukemia: The AUGMENT-101 Study." Blood 146, no. 9 (2025): 1065. https://doi.org/10.1182/blood.2025028357.

MLA (9th ed.) Citation

ML, Arellano, et al. "Menin Inhibition with Revumenib for NPM1-mutated Relapsed or Refractory Acute Myeloid Leukemia: The AUGMENT-101 Study." Blood, vol. 146, no. 9, 2025, p. 1065, https://doi.org/10.1182/blood.2025028357.